Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

About this update from Sight Sciences, Inc.

Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that the U.S. District Court for the District of Delaware (the Court) issued an order on post-trial motions in Sight Sciences’ patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon) originally filed on September 16, 2021, that preserved the jury’s verdict of willful infringement. Sight Sciences asserted that Alcon’s sale of the Hydrus® Microstent (Hydrus) infringed three Sight Sciences patents. The Court’s order was entered on March 27, 2026. The order (i) did not disturb the jury’s verdict that Alcon willfully infringed all three of Sight Sciences’ asserted patents and (ii) awarded monetary damages of $34 million, plus supplemental damages and interest, for past infringement, plus an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, the date of expiration of Sight Sciences’ last asserted patent. A final judgment is expected to be entered by the Court in the coming months after supplemental damages and pre-judgment interest have been calculated. The Court’s final judgment is subject to appeal by Alcon. Judgment Overview “We are pleased with the results of the ruling and the recognition of our strong intellectual property portfolio in interventional glaucoma. Since 2006, Sight Sciences has been committed to elevating the standard of glaucoma care by pioneering and developing the field of circumferential microinvasive glaucoma surgery,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “We believe safeguarding our intellectual property, which includes both microinvasive glaucoma implants as well as microcatheter-based canaloplasty devices, is critical. It allows us to continue investing in our pipeline of additional interventional innovations with the goal of further elevating the standard of care on behalf of our surgeon customers and their glaucoma patients.” The Compa...

View stock analysis, news, and events for Sight Sciences, Inc.